414 related articles for article (PubMed ID: 19681866)
1. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ; Cassidy RS; Green BD
Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
[TBL] [Abstract][Full Text] [Related]
2. The cardiovascular effects of GLP-1 receptor agonists.
Okerson T; Chilton RJ
Cardiovasc Ther; 2012 Jun; 30(3):e146-55. PubMed ID: 21167014
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.
Del Olmo-Garcia MI; Merino-Torres JF
J Diabetes Res; 2018; 2018():4020492. PubMed ID: 29805980
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.
Ryan D; Acosta A
Obesity (Silver Spring); 2015 Jun; 23(6):1119-29. PubMed ID: 25959380
[TBL] [Abstract][Full Text] [Related]
5. Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies.
Prajapati S
Curr Diabetes Rev; 2024; 20(7):e131123223544. PubMed ID: 37962047
[TBL] [Abstract][Full Text] [Related]
6. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.
Jiang H; Zang L
Curr Pharm Des; 2024; 30(2):100-114. PubMed ID: 38532322
[TBL] [Abstract][Full Text] [Related]
7. Incretin and glucagon receptor polypharmacology in chronic kidney disease.
McFarlin BE; Duffin KL; Konkar A
Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E747-E766. PubMed ID: 38477666
[TBL] [Abstract][Full Text] [Related]
8. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.
Marrano N; Biondi G; Borrelli A; Cignarelli A; Perrini S; Laviola L; Giorgino F; Natalicchio A
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671882
[TBL] [Abstract][Full Text] [Related]
9. Incretins beyond type 2 diabetes.
Mathieu C; Ahmadzai I
Diabetologia; 2023 Oct; 66(10):1809-1819. PubMed ID: 37552238
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular safety of incretin-based therapies: a review of the evidence.
Petrie JR
Cardiovasc Diabetol; 2013 Sep; 12():130. PubMed ID: 24011363
[TBL] [Abstract][Full Text] [Related]
11. Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice.
Camilleri M; Lupianez-Merly C
Am J Gastroenterol; 2024 Jun; 119(6):1028-1037. PubMed ID: 37753925
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
Ussher JR; Drucker DJ
Nat Rev Cardiol; 2023 Jul; 20(7):463-474. PubMed ID: 36977782
[TBL] [Abstract][Full Text] [Related]
13. Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd CM; Bjornstad P; van Raalte DH
J Nephrol; 2020 Oct; 33(5):965-975. PubMed ID: 32356231
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp KO; Glotfelty EJ; Li Y; Lahiri DK; Greig NH
Ageing Res Rev; 2024 Jul; 98():102343. PubMed ID: 38762101
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and hemodynamic effects of glucagon-like peptide-1.
Goodwill AG; Mather KJ; Conteh AM; Sassoon DJ; Noblet JN; Tune JD
Rev Endocr Metab Disord; 2014 Sep; 15(3):209-17. PubMed ID: 24881624
[TBL] [Abstract][Full Text] [Related]
16. The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis.
Conroy LJ; McCann A; Zhang N; de Gaetano M
Am J Physiol Cell Physiol; 2024 May; 326(5):C1398-C1409. PubMed ID: 38525540
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.
Tommerdahl KL; Nadeau KJ; Bjornstad P
Adv Chronic Kidney Dis; 2021 Jul; 28(4):337-346. PubMed ID: 34922690
[TBL] [Abstract][Full Text] [Related]
18. Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss.
Buller S; Blouet C
Am J Physiol Endocrinol Metab; 2024 Apr; 326(4):E472-E480. PubMed ID: 38381398
[TBL] [Abstract][Full Text] [Related]
19. Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.
Allard C; Cota D; Quarta C
Drugs; 2024 Feb; 84(2):127-148. PubMed ID: 38127286
[TBL] [Abstract][Full Text] [Related]
20. Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.
Capone F; Nambiar N; Schiattarella GG
Curr Opin Cardiol; 2024 May; 39(3):148-153. PubMed ID: 38294187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
